Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.

By D. Graham, D. Campen, R. Hui, Michele M. Spence, C. Cheetham, Gérald Lévy, S. Shoor, W. Ray. The Lancet, 2005

871 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. (2006, background): “Seven studies also reported RRs of cardiovascular events estimated from between-drug agent comparisons.(3,4,16,23,24,27,32) Where possible, we also extracted and summarized data from these analyses.”
The Role of COX-2 in Intestinal Inflammation and Colorectal Cancer (2009, neutral): “Another cohort study examined cardiovascular outcomes in approximately 1.4 million patients receiving NSAIDs or COXIBs showed that there was, again, no risk observed Oncogene with celecoxib (Graham et al., 2005).”